H. Lundbeck A/S v Sandoz Pty Ltd; CNS Pharma Pty Ltd v Sandoz Pty Ltd [2022] HCA 4Date:Court:Judges:9 March 2022High Court of AustraliaGaegler, Edelman, Steward and Gleeson...
Vector Corrosion fails to cement entitlement claim
Vector Corrosion Technologies Limited v E-Chem Technologies Ltd [2022] FCA 188 Date:Court:Judge:9 March 2022Federal Court of AustraliaJagot JBackground Vector Corrosion...
Removing Patent Barriers in Australia
In this 55 minute Masterclass, a panel of award winning senior Pearce IP lawyers and patent attorneys discussed the strategic options available to challenge patent rights in Australia, and the ideal circumstances in which each option might be deployed.
Pearce IP BioBlast w/e 11 March 2022
03 Mar 22 | US | FDA announced a new funding opportunity for the BsUFA III Regulatory Science Program to support research projects that “enhance biosimilar and interchangeable...
Pearce IP honours its high achieving women on International Women’s Day
As a female led boutique firm, Pearce IP celebrates the successes of its high achieving women on International Women’s Day. Each of Pearce IP’s CEO, and heads of litigation and...
Reminder – new .au domain names coming to Australia from 24 March 2022
We previously wrote that, from 24 March 2022, individuals, businesses and organisations with an Australian presence will be able to apply to register a domain name of their...
Pearce IP BioBlast w/e 25 February 2022
18 Feb 22 | Celltrion released two data sets on the subcutaneous (SC) form of Remsima® (biosimilar infliximab). Celltrion reported that switching from IV to SC infliximab leads...
Why Preparedness Is So Pivotal
In this Boutique Lawyer Show podcast, Pearce IP’s CEO and Executive Naomi Pearce speaks candidly with Lawyers Weekly’s Jerome Doraisamy.
Nothing inventive in the electronic operation and configuration of fitness studios
F45 Training Pty Ltd v Body Fit Training Company Pty Ltd (No 2) [2022] FCA 96 Date:Court:Judge:15 February 2022Federal Court of AustraliaNicholas JBackground F45 Training Pty Ltd...
Pearce IP BioBlast 18 February 2022
11 Apr 22 | CA | Celltrion announced the launch of Yuflyma® (high-concentration, low-volume, citrate-free and latex-free biosimilar adalimumab) in Canada. Yuflyma® is approved...
Interlocutory injunction to restrain further threats of patent infringement granted in car park scrap
UbiPark Pty Ltd v TMA Capital Australia Pty Ltd [2022] FCA 111 Date:Court:Judge:14 February 2022Federal Court of AustraliaMohinsky JBackground UbiPark Pty Ltd (UbiPark) and...
PTE alert: Patent Office cancellation of PTE paves the way for potential launch of generic YASMIN products
We have previously reported on a number of Federal Court decisions in 2021 invalidating patent term extensions (PTEs) in Australia: Biogen International GmbH v Pharmacor Pty Ltd...
Pearce IP BioBlast w/e 11 February 2022
07 Feb 22 | The International Generic and Biosimilar medicines Association (IGBA) announced that it has established a CEO Advisory Committee. Committee members represent Amneal...
Patent Office cancellation of PTE paves the way for potential launch of generic YASMIN products
Bayer Pharma Aktiengesellschaft [2022] APO 7Date:Venue:Delegate:7 February 2022Australian Patent OfficeKeith WraggBackground In our 2021 Patent Case summary, we reported on a...
Pearce IP BioBlast w/e 04 February 2022
01 Feb 22 | JAMP Pharma announced the creation of a new division BIOJAMP™ dedicated to biosimilars. The creation of this division was primarily made possible through JAMP’s...
Comments period on draft new National Medicines Policy extended – now closing on 2 March
Last week we alerted you to the release of a draft new National Medicines Policy (NMP) for public comment. The draft NMP was released by the National Medicines Policy Review...
No time to lose! Comments on the consultation draft of the new National Medicines Policy close on 16 February
On 2 February a draft of a new National Medicines Policy (NMP) was made available for public comment. The draft NMP was released by the National Medicines Policy Review...
Pearce IP BioBlast® f/e 31 January 2022
18 Jan 22 | Alvotech announced $21 million in additional commitments for private placement (PIPE) of Oaktree II common stock. Alvotech and Oaktree Acquisition Corp. II...
Pearce recognised as a World Leading IP Strategist by IAM
Pearce IP is proud to announce that Founding Principal and Executive Lawyer, Patent & Trade Mark Attorney, Naomi Pearce, has again been listed in the 2022 edition of IAM...
Pearce IP BioBlast® w/e 14 January 2022
10 Jan 22 | CA | Alvotech and JAMP Pharma announced that Health Canada has approved Simlandi (high-concentration, citrate-free biosimilar adalimumab). 11 Jan 22 | EU | Orion...
Pearce IP BioBlast® w/e 07 January 2022
30 Dec 21 | US | Biocon Biologics announced that the US Court of Appeals for the Federal Circuit Court has upheld the US Patent and Trademark Appeal Board’s decisions of...
Pfizer quest for Samsung Bioepis etanercept documents continues
Shortly before Christmas, the judgment handed down by Justice Burley on 18 November 2021 on a second preliminary discovery application made by Pfizer seeking documents from...
Pearce IP BioBlast® 31 December 2021
20 Dec 21 | US | Sandoz announced that it has submitted a BLA to the FDA for a proposed biosimilar trastuzumab. 20 Dec 21 | US | The FDA approved Eli Lilly’s Rezvlogar®...
PTE Alert (part 2): Bad Patent Term Extension Enables Generics to Avoid Preliminary Injunction in Australia
Newly appointed Justice Rofe delivered an early Christmas gift for generic and biosimilar companies in Australia in the Biogen v Pharmacor reasons delivered yesterday. We...
Recent BioBlast® Updates
Get our Pearce IP Blogs & BioBlast® sent directly to your inbox
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.